Skip to Content

Syneos Health Inc Class A SYNH Stock Quote

| Rating as of

Morningstar‘s Stock Analysis SYNH

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Narrow-Moat Syneos Reports Softened Q2 Results; Shares Fairly Valued, $69 FVE

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

Narrow-moat Syneos reported softened second-quarter results due to lower reimbursable expenses in the Clinical Solutions segment and foreign exchange headwinds. The unexpected decrease in reimbursable expenses was related to lower investigator payments on its COVID portfolio, the impact of an FDA-related delay, and the wind down of a large program. Investors reacted quite negatively to Syneos’ earnings and sent the stock down nearly 18% at close of day. We believe investors overreacted to the earnings results, as the headwinds are likely less impactful in the long-term.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics SYNH

Company Profile SYNH

Business Description

Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company’s commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

Contact
1030 Sync Street
Morrisville, NC, 27560-5468
T +1 919 876-9300
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type Classic Growth
Employees 27,525